1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Estonia Pharmaceuticals and Healthcare Report Q3 2016

Estonia Pharmaceuticals and Healthcare Report Q3 2016

  • May 2016
  • -
  • Business Monitor International
  • -
  • 86 pages

Includes 3 FREE quarterly updates

BMI View: Estonia's healthcare system is much more mature than its Central and Eastern European peers,but given the country's limited resources, the country is less appealing to pharmaceutical companies.Drugmakers can expect to see constrained revenue growth in the country as pricing pressures andrestrictive drug reimbursement are employed by the Estonian health insurance fund to restrict healthcareexpenditure.

Headline Expenditure Projections

- Pharmaceuticals: Sales will rise from EUR310mn (USD344mn) in 2015 to EUR328mn (USD350mn) in2016, up 5.8% in local currency terms and up 2.0% in US dollar terms. Forecast has been maintainedfrom last quarter.

- Healthcare: Spending will rise from EUR1.30bn (USD1.44bn) in 2015 to EUR1.36bn (USD1.46bn) in2016, up 4.9% in local currency terms and up 1.46% in US dollar terms. Forecast has beenincreased from last quarter.

Table Of Contents

Estonia Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Estonia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Estonia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020) 16
Prescription Drug Market Forecast 17
Table: Leading Anatomical Therapeutic Chemical (ATC) Groups By Pharmaceutical Sales, 2004-2010 (%) 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Estonia 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Estonia 2014-2020) 30
Pharmaceuticals Risk/Reward Index 31
Central And Eastern Europe Risk/Reward Index - Q3 2016 31
Estonia Risk/Reward Index 37
Rewards 37
Risks 37
Regulatory Review 39
Intellectual Property Issues 42
Pricing Regime 43
Reimbursement Regime 44
Table: Key Health Insurance Indicators, 2007-2011 44
Table: Expenditure By Reimbursed Prescription Medicinal Products, 2005-2010 (EEK '000) 46
Market Overview 48
Healthcare Sector 49
Table: Healthcare Resources (Estonia 2010-2015) 51
Table: Healthcare Personnel (Estonia 2010-2015) 52
Table: Healthcare Activity (Estonia 2010-2015) 52
Table: HIF Healthcare Expenditure, 2006-2011 (EURmn) 53
Table: Reimbursement Spending By Key Therapeutic Area, 2010-2011 (EURmn) 55
Table: Medicinal Products Reimbursed For Insured Patients, 2009-2011 (EURmn) 56
Research And Development 57
Table: Members Of EBio, 2011 57
Clinical Trials 59
Table: Leading Causes Of Death, 2005-2010 62
Competitive Landscape 64
Research-Based Industry 64
Table: Members Of The Association Of International Pharmaceutical Manufacturers In Estonia 65
Table: Table: Multinational Market Activity 65
Generic Drugmakers 66
Pharmaceutical Distribution 67
Pharmaceutical Retail Sector 68
Table: Pharmacies And Pharmacy Market Ratios, 2004-2009 69
Company Profile 71
Grindeks (incorporating Tallinn Pharmaceutical Plant) 71
Demographic Forecast 75
Table: Population Headline Indicators (Estonia 1990-2025) 76
Table: Key Population Ratios (Estonia 1990-2025) 76
Table: Urban/Rural Population and Life Expectancy (Estonia 1990-2025) 77
Table: Population By Age Group (Estonia 1990-2025) 77
Table: Population By Age Group % (Estonia 1990-2025) 78
Glossary 80
Methodology 82
Pharmaceutical Expenditure Forecast Model 82
Healthcare Expenditure Forecast Model 82
Notes On Methodology 83
Risk/Reward Index Methodology 84
Index Overview 85
Table: Pharmaceutical Risk/Reward Index Indicators 85
Indicator Weightings 86

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.